Skip to Content


In the US, Fingolimod (fingolimod systemic) is a member of the drug class selective immunosuppressants and is used to treat Multiple Sclerosis.

US matches:



ATC (Anatomical Therapeutic Chemical Classification)


CAS registry number (Chemical Abstracts Service)


Chemical Formula


Molecular Weight


Therapeutic Categories

Selective immunosuppressant

Treatment of multiple sclerosis, MS

Sphingosine 1-phosphate (S1P) receptor modulator

Chemical Name

2-amino-2-[2-(4-octylphenyl]etylpropane-1,3-diol (WHO)

Foreign Names

  • Fingolimodum (Latin)
  • Fingolimod (German)
  • Fingolimod (French)
  • Fingolimod (Spanish)

Generic Names

Brand Names

  • Emulimod
    Varifarma, Argentina
  • Fibroneurina
    Bago, Argentina
  • Fingolimod
    Accord Healthcare, United States; Alkem, United States; Aurobindo Pharma USA, United States; Biocon, United States; Glenmark Generics, United States; Par Pharmaceutical, United States; Strides Pharma, United States; Teva, United States
  • Fingya
    Farmanova, Turkey
  • Gilenya
    Novartis, Colombia; Novartis, Lithuania; Novartis, Poland; Novartis, Thailand; Novartis, Tunisia; Novartis, United States; Novartis Biosciences, Peru; Novartis Europharm, Cyprus; Novartis Europharm, Greece; Novartis PHarma Services Inc., Serbia; Novartis Pharmaceuticals, Australia; Novartis, Slovenia
  • Gilenya 0.5mg
    Novartis, Oman
  • Vintor
    Sanovel, Turkey
  • Gilenia
    Novartis Pharma, Russian Federation
  • Gilenya
    Novartis, Argentina; Novartis, Bosnia & Herzegowina; Novartis, Belgium; Novartis, Brazil; Novartis, Chile; Novartis, Czech Republic; Novartis, Denmark; Novartis, Estonia; Novartis, Finland; Novartis, France; Novartis, Georgia; Novartis, Hong Kong; Novartis, Croatia (Hrvatska); Novartis, Ireland; Novartis, Japan; Novartis, Latvia; Novartis, Macedonia; Novartis, Malaysia; Novartis, Netherlands; Novartis, Norway; Novartis, New Zealand; Novartis, Portugal; Novartis, Sweden; Novartis, Slovakia; Novartis Europharm, Romania; Novartis Europharm Limited, Iceland; Novartis Farmaceutica, Spain; Novartis Pharma, Germany; Novartis Pharmaceuticals, Canada; Novartis Pharmaceuticals UK, United Kingdom; Novartis Singapore, Singapore
  • Gilenya 0.5mg
    Abacus, Austria; Emra-Med Arzneimittel, Austria; Eurim-Pharm, Austria; Haemato Pharm, Austria; NewNeopharm, Austria; Novartis, Hungary; Novartis, Israel; Novartis, Luxembourg; Novartis Europharm, Austria; Novartis Pharma, Switzerland; Orifarm, Austria
  • Imusera
    Tanabe Mitsubishi Pharma, Japan
  • Lebrina
    Raffo, Argentina
  • Modina
    LKM, Argentina
  • Mogibe
    Tuteur, Argentina


BANBritish Approved Name
BANMBritish Approved Name (Modified)
ISInofficial Synonym
JANJapanese Accepted Name
OSOfficial Synonym
PHPharmacopoeia Name
Rec.INNRecommended International Nonproprietary Name (World Health Organization)
USANUnited States Adopted Name
WHOWorld Health Organization

Further information on drug naming conventions: International Nonproprietary Names.

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.